Google
UTHR 株価分析 — United Therapeutics Corporation (Healthcare >> Drug Manufacturers - Specialty & Generic)
UTHR に関するよくある質問
UTHRのPER（株価収益率）は？
United Therapeutics Corporation（UTHR）は現在PER 20.34倍で取引されています。
UTHRのROE（自己資本利益率）は？
United Therapeutics CorporationのROEは21.82%です。
UTHRの配当利回りは？
United Therapeutics Corporationの配当利回りは0.00%です。
UTHRの品質スコア（Quality Score）は？
当社のAIはUTHRの総合財務品質を100点中85点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
UTHRは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
UTHRはどのセクターに属しますか？
United Therapeutics CorporationはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
UTHR AI Analysis Summary
Our AI summary for UTHR: United Therapeutics Corporation (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 20.34, ROE of 21.82%, a dividend yield of 0.00%. Its financial Quality Score stands at 85/100 — fundamentals stronger than most of the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 517.71
Price
-8.11
(-1.54%)
Day Change
|
|
|---|
UTHR, ファンダメンタルスコアはvery good ( ファンダメンタル = 85) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROEの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
57% |
| In Recommendations? | In "Invest - GOOD" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.12 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
654
|
| Magic Formula Rank by ROE |
654
|
| Magic Formula Rank by ROIC |
694
|
| Price | 517.71 |
| PBV / Sector |
4.44 / 3.22
|
| Earning Per Share | 25.45 |
| PE / Sector |
20.34 / 29.79
|
| PEG or PE/Growth / Sector |
0.88 / 0.13
|
| Average 1M Daily Value |
190.11 M
GREAT
|
| Average 1W Daily Value |
198.37 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
58% |
| ポイントになる統計 |
|
72% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:38 |
| Symbol | UTHR |
| Name | UNITED THERAPEUTICS CORPORATION |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 49.80 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 26,186.95 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1000 Spring Street, Silver Spring, MD, United States, 20910
Phone: 301 608 9292
Website: https://www.unither.com
Employees: 1,400
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
